Method for determining risk of adverse event

Abstract

A method for determining a risk of an adverse event during multimodal treatment is provided. A method for determining a risk of an adverse event during multimodal treatment includes measuring Anaerostipes hadrus in a sample collected from a subject.

1 : A method for determining a risk of an adverse event during multimodal treatment, comprising:
 measuring  Anaerostipes hadrus  in a sample collected from a subject.   
     
     
         2 : The method according to  claim 1 , wherein the risk of an adverse event is a risk of onset or exacerbation of an adverse event. 
     
     
         3 : The method according to  claim 1 , wherein the multimodal treatment is a drug therapy, a surgical therapy, radiation treatment, and a combination thereof. 
     
     
         4 : The method according to  claim 1 , wherein the multimodal treatment is a drug therapy. 
     
     
         5 : The method according to  claim 1 , wherein the adverse event is at least one of febrile neutropenia and diarrhea. 
     
     
         6 : The method according to  claim 1 , wherein the sample is a fecal sample of the subject. 
     
     
         7 : The method according to  claim 1 , further comprising:
 comparing a number of bacteria of  Anaerostipes hadrus  in the sample with a reference value; and   determining that the risk of an adverse event during the multimodal treatment is high when the number of bacteria is equal to or less than the reference value.   
     
     
         8 : The method according to  claim 1 , further comprising:
 comparing an occupancy rate of  Anaerostipes hadrus  in total bacteria in the sample with a reference value; and   determining that the risk of an adverse event during the multimodal treatment is high when the occupancy rate is equal to or less than the reference value.   
     
     
         9 : The method according to  claim 1 , further comprising:
 determining that a risk of febrile neutropenia during the multimodal treatment is high when a number of bacteria of  Anaerostipes hadrus  in the sample is 10 7.7  or less per gram of the sample or an occupancy rate of  Anaerostipes hadrus  in total bacteria in the sample is 0.25% or less.   
     
     
         10 : The method according to  claim 1 , further comprising:
 determining that a risk of diarrhea during the multimodal treatment is high when a number of bacteria of  Anaerostipes hadrus  in the sample is 10 7.6  or less per gram of the sample or an occupancy rate of  Anaerostipes hadrus  in total bacteria in the sample is 0.084% or less.   
     
     
         11 : A kit for carrying out the method of  claim 1 , comprising:
 a measurement reagent; and   a protocol for  Anaerostipes hadrus  in the sample.   
     
     
         12 : A method for screening for an agent for reducing the risk of an adverse event during multimodal treatment, comprising:
 using a number of bacteria or an occupancy rate of  Anaerostipes hadrus  as an index.   
     
     
         13 : The method according to  claim 1 , wherein the adverse event is febrile neutropenia. 
     
     
         14 : The method according to  claim 1 , wherein the adverse event is diarrhea. 
     
     
         15 : The method according to  claim 2 , wherein the multimodal treatment is a drug therapy, a surgical therapy, radiation treatment, and a combination thereof. 
     
     
         16 : The method according to  claim 2 , wherein the multimodal treatment is a drug therapy. 
     
     
         17 : The method according to  claim 2 , wherein the adverse event is at least one of febrile neutropenia and diarrhea. 
     
     
         18 : The method according to  claim 2 , wherein the sample is a fecal sample of the subject. 
     
     
         19 : The method according to  claim 2 , further comprising:
 comparing a number of bacteria of  Anaerostipes hadrus  in the sample with a reference value; and   determining that the risk of an adverse event during the multimodal treatment is high when the number of bacteria is equal to or less than the reference value.   
     
     
         20 : The method according to  claim 2 , further comprising:
 comparing an occupancy rate of  Anaerostipes hadrus  in total bacteria in the sample with a reference value; and   determining that the risk of an adverse event during the multimodal treatment is high when the occupancy rate is equal to or less than the reference value.